Current Hematologic Malignancy Reports
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. 
Subscribe to this data using MyMedWorm.
Subscribe to this data using GoogleReader.
Subscribe to this data using Bloglines.
Subscribe to this data using MyYahoo.
Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.
This page shows you the latest items in this publication.
96 records returned
Prognostic factors in low-grade non-Hodgkin lymphomas
Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Abstract Low-grade non-Hodgkin lymphomas were once considered as a heterogenous group of lymphomas characterized by an indolent clinical
course. Today, low-grade non-Hodgkin lymphomas are classified as a group of 10 distinct entities, each characterized by unique
clinico biologic features. Follicular lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, lymphoplasmacytic
lymphoma, and marginal zone lymphoma are the most-investigated subtypes. Several studies have been performed to identify prognostic
factors specific for each subtype in an effort to help clinicians in treatment decisions. The fi...
Source: Current Hematologic Malignancy Reports - September 30, 2009 Category: Hematology Tags: Current Hematologic Malignancy Reports Source Type: journals
The host-tumor interface in B-cell non-Hodgkin lymphoma: A new world to investigateEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Abstract Research on B-cell non-Hodgkin lymphoma focuses mainly on oncogenic events occurring in lymphoma cells, but recently a new
component has appeared that may be crucial in lymphomagenesis: the tumor microenvironment. Indeed, compelling evidence demonstrates
the key role played by nonmalignant bystander cells in the establishment and proliferation of the tumor. Among these cells,
stromal cells, monocytes/macrophages, and T cells in lymphoid organs have all been described as contributing to tumor progression.
Interactions linked to cell-cell intimate contacts—but also mediated through soluble mediators...
Source: Current Hematologic Malignancy Reports - September 30, 2009 Category: Hematology Tags: Current Hematologic Malignancy Reports Source Type: journals
Beyond R-CHOP and the IPI in large-cell lymphoma: Molecular markers as an opportunity for stratificationEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
This article reviews the history of DLBCL, prognostic factors, therapy, and possible future directions.
Content Type Journal ArticleDOI 10.1007/s11899-009-0029-yAuthors
Jason R. WestinLuis E. Fayad, University of Texas M. D. Anderson Cancer Center Department of Lymphoma/Myeloma 1515 Holcombe Boulevard, Unit #429 Houston TX 77030 USA
Journal Current Hematologic Malignancy ReportsOnline ISSN 1558-822XPrint ISSN 1558-8211
Journal Volume Volume 4
Journal Issue Volume 4, Number 4 / October, 2009 (Source: Current Hematologic Malignancy Reports)
Source: Current Hematologic Malignancy Reports - September 30, 2009 Category: Hematology Tags: Current Hematologic Malignancy Reports Source Type: journals
Hemopoietic stem cell transplantation in T-cell malignancies: Who, when, and how?Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
This article reviews the most recent results
of upfront HDT/ASCT consolidation in different subtypes of systemic PTCL. The data on allogeneic stem cell transplantation
are more limited, but promising results have recently been reported in the setting of relapsed or primary refractory disease.
Content Type Journal ArticleDOI 10.1007/s11899-009-0031-4Authors
Francesco d’Amore, Aarhus University Hospital Department of Hematology Tage Hansens Gade 2 DK-8000 Aarhus C DenmarkEsa JantunenThomas Relander
Journal Current Hematologic Malignancy ReportsOnline ISSN 1558-822XPrint ISSN 1558-8211
Journal Volume Volum...
Source: Current Hematologic Malignancy Reports - September 30, 2009 Category: Hematology Tags: Current Hematologic Malignancy Reports Source Type: journals
Update on the World Health Organization classification of peripheral T-cell lymphomasEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Abstract Peripheral T-cell lymphomas (PTCLs) are a rare and heterogeneous group of lymphoproliferative disorders of postthymic origin.
Progress in elucidating the pathobiology and appropriate therapy of these neoplasms has been slow, primarily because of their
rarity, but also because until the early 1990s, they were generally grouped together and combined with B-cell lymphomas. It
is now understood that most PTCLs are highly aggressive and respond poorly to standard chemo therapy, and thus they have a
significantly poorer prognosis than their B-cell counterparts. In 1994, the Revised European and American L...
Source: Current Hematologic Malignancy Reports - September 30, 2009 Category: Hematology Tags: Current Hematologic Malignancy Reports Source Type: journals
Natural killer-cell neoplasmsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Abstract The natural killer (NK)-cell neoplasms are rare, representing less than 1% of non-Hodgkin lymphoma, except in Asia and Latin
America, where they represent 3% to 6%. NK-cell neoplasms include immature acute leukemias; a blastic NK-cell lymphoma, which
is obsolete because of its plasmacytoid dendritic-cell origin; and mature NK neoplasms, comprising extranodal NK/T-cell lymphoma
(ENKL), nasal-type; aggressive NK-cell leukemia; and chronic NK-cell lymphoproliferative disorders, which are often reactive.
Epstein-Barr virus is usually detected in tumor cells of ENKL and aggressive NK-cell leukemia. The l...
Source: Current Hematologic Malignancy Reports - September 30, 2009 Category: Hematology Tags: Current Hematologic Malignancy Reports Source Type: journals
Antilymphoma therapy with a Bcl-6 inhibitorEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Content Type Journal ArticleCategory Clinical Trials ReportDOI 10.1007/s11899-009-0033-2Authors
Peter McLaughlin, The University of Texas M. D. Anderson Cancer Center Department of Lymphoma/Myeloma Houston USA
Journal Current Hematologic Malignancy ReportsOnline ISSN 1558-822XPrint ISSN 1558-8211
Journal Volume Volume 4
Journal Issue Volume 4, Number 4 / October, 2009 (Source: Current Hematologic Malignancy Reports)
Source: Current Hematologic Malignancy Reports - September 30, 2009 Category: Hematology Tags: Current Hematologic Malignancy Reports Source Type: journals
Vaccination strategies in follicular lymphomaEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Abstract Follicular lymphoma is one of the most immuneresponsive cancers. The clonal tumor immunoglobulin expressed on the surface
of malignant B cells, termed idiotype, has been used as a tumor-specific antigen in therapeutic vaccination strategies for follicular lymphoma and other B-cell
malignancies. A number of phase 1 and phase 2 clinical trials have established the safety and immunogenicity of idiotype vaccine
in follicular lymphoma. Three randomized, double-blind, controlled phase 3 clinical trials have recently been completed to
definitively evaluate the clinical benefit of idiotype vaccine in follic...
Source: Current Hematologic Malignancy Reports - September 30, 2009 Category: Hematology Tags: Current Hematologic Malignancy Reports Source Type: journals
Frontline therapy in mantle cell lymphoma: The role of high-dose therapy and integration of new agentsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Abstract Mantle cell lymphoma (MCL) is a unique lymphoma subtype comprising 6% to 8% of new lymphoma diagnoses. It is generally considered
to be incurable with standard lymphoma therapies. The median overall survival (OS) is often reported to be 3 to 4 years, but
more recent data suggest that the median OS may be longer than 5 years. There is considerable heterogeneity in MCL, with some
patients succumbing to their disease in less than a year and others surviving for more than 10 years. The biology of MCL is
reasonably well understood, and targeted therapies based on this knowledge are in development. Clinic...
Source: Current Hematologic Malignancy Reports - September 30, 2009 Category: Hematology Tags: Current Hematologic Malignancy Reports Source Type: journals
Chemoimmunotherapy with modified dosing of fludarabine, cyclophosphamide, and rituximab shows significant clinical activity in patients with previously untreated chronic lymphocytic leukemiaEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Content Type Journal ArticleCategory Clinical Trials ReportDOI 10.1007/s11899-009-0034-1Authors
Nicole Lamanna, Leukemia Service at Memorial Sloan-Kettering Cancer Center New York NY USAMark A. Weiss, Leukemia Service at Memorial Sloan-Kettering Cancer Center New York NY USA
Journal Current Hematologic Malignancy ReportsOnline ISSN 1558-822XPrint ISSN 1558-8211
Journal Volume Volume 4
Journal Issue Volume 4, Number 4 / October, 2009 (Source: Current Hematologic Malignancy Reports)
Source: Current Hematologic Malignancy Reports - September 30, 2009 Category: Hematology Tags: Current Hematologic Malignancy Reports Source Type: journals
What is the best treatment for children with limited-stage Hodgkin lymphoma?Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Abstract Limited-stage Hodgkin lymphoma remains a challenging problem for pediatric oncologists. Published and investigative treatment
regimens represent varied approaches to balance the excellent overall and event-free survival with the substantial potential
for long-term sequelae of effective treatment modalities. Regimens incorporating low-dose radiation to smaller fields and
chemotherapy that limits cumulative exposure to the agents most closely associated with long-term complications have been
shown to be effective for most patients. Investigative approaches to optimize overall therapy focus on identify...
Source: Current Hematologic Malignancy Reports - June 30, 2009 Category: Hematology Tags: Current Hematologic Malignancy Reports Source Type: journals
Novel therapies for relapsed acute lymphoblastic leukemiaEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Abstract The outcome of salvage therapy for relapsed acute lymphoblastic leukemia (ALL) remains poor. Salvage therapy mimics regimens
with activity in newly diagnosed ALL. Novel strategies under investigation as monotherapy or in combination with chemotherapy
improve the treatment of relapsed disease. For some ALL subsets, specific therapies are indicated. The addition of targeted
therapy in Philadelphia chromo some-positive ALL has improved responses in relapsed patients without resistance to available
tyrosine kinase inhibitors. Nelarabine demonstrates activity as monotherapy in T-cell ALL and is approved ...
Source: Current Hematologic Malignancy Reports - June 30, 2009 Category: Hematology Tags: Current Hematologic Malignancy Reports Source Type: journals
Infant acute lymphoblastic leukemia: Lessons learned and future directionsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Abstract Compared with acute lymphoblastic leukemia (ALL) in older children, ALL in infants has a dismal outcome because rearrangements
of the mixed-lineage leukemia (MLL) gene occur in about 80% of these patients, leading to an aggressive type of leukemia. With most recent therapies, about
50% long-term event-free survival is achieved, but early bone marrow relapse remains a major problem. Early intensification
of chemotherapy and new innovative therapies are necessary to improve outcome. Bone marrow transplantation should be limited
to a small subset of well-recognized ALL patients with a very poor prognos...
Source: Current Hematologic Malignancy Reports - June 30, 2009 Category: Hematology Tags: Current Hematologic Malignancy Reports Source Type: journals
Does radiotherapy still have a place in Hodgkin lymphoma?Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Abstract Over half a century, radiation therapy (RT) for Hodgkin lymphoma has been transformed from a radical, extensive, high-dose
therapy (which alone cured most patients) into an essential component of a comprehensive combined-modality program. RT is
now used in a “mini” version that encompasses only the clinically involved sites following chemotherapy and is administered
in a markedly reduced dose. This change has considerably reduced the long-term complications that were associated with the
now-outdated radical RT approach. The use of RT also allows a shorter and safer course of chemotherapy. The co...
Source: Current Hematologic Malignancy Reports - June 30, 2009 Category: Hematology Tags: Current Hematologic Malignancy Reports Source Type: journals
Application of immunotherapy in pediatric leukemiaEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Abstract Despite great progress in the curative treatment of leukemia in pediatrics, current therapies are associated with multiple
toxicities and the prognosis after relapse is guarded. Novel approaches are needed to overcome resistance to standard therapy
and decrease adverse effects. The efficacy of allogeneic stem cell transplantation and the demonstration of a graft-versus-leukemia
effect suggest that immune-based therapies can be effective in the treatment of childhood leukemia. Efforts to apply new immunotherapy
approaches to the treatment of leukemia in pediatrics have recently begun. The optimal rea...
Source: Current Hematologic Malignancy Reports - June 30, 2009 Category: Hematology Tags: Current Hematologic Malignancy Reports Source Type: journals
Update on developmental therapeutics for acute lymphoblastic leukemiaEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Abstract This is an exciting time in drug development for acute lymphoblastic leukemia (ALL). A confluence of trends makes it likely
that highly effective new agents for ALL will be identified in the coming decade. One contributory factor is the development
of more representative preclinical models of ALL for testing and prioritizing novel agents. Another important trend in ALL
drug development is the increasing understanding at the molecular level of the genomic changes that occur in B-precursor and
T-cell ALL. A final important trend is the increasing availability of new agents against relevant molecular t...
Source: Current Hematologic Malignancy Reports - June 30, 2009 Category: Hematology Tags: Current Hematologic Malignancy Reports Source Type: journals
Allogeneic hematopoietic stem cell transplantation for adult acute lymphocytic leukemiaEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Abstract Allogeneic hematopoietic stem cell transplantation (alloHCT) is the single most potent treatment modality to prevent relapse
in adults with acute lymphocytic leukemia, but its optimal use and timing remains a matter of intense debate and research.
There is general agreement that patients with clinical features of high risk for relapse should undergo alloHCT in first complete
remission. However, newer studies suggest that even patients without these risk factors may benefit. Monitoring of minimal
residual disease may improve risk stratification and may complement or replace conventional risk features...
Source: Current Hematologic Malignancy Reports - June 30, 2009 Category: Hematology Tags: Current Hematologic Malignancy Reports Source Type: journals
Is Hodgkin lymphoma just another B-cell lymphoma?Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
This article reviews the different aspects of HL and
B-cell non-Hodgkin lymphoma (B-NHL), concluding that—despite the same cell of origin—fundamental differences exist in morphology,
cellular composition, immunophenotype, activation or inhibition of transcription factors, epigenetics, and clinical behavior.
These findings lead us to conclude that HL and B-NHLs should stay as two separate categories.
Content Type Journal ArticleDOI 10.1007/s11899-009-0018-1Authors
Harald Stein, Charité University of Medicine Pathology Institute, Campus Benjamin Franklin Hindenburgdamm 30 12200 Berlin GermanyRoshanak Bob
...
Source: Current Hematologic Malignancy Reports - June 30, 2009 Category: Hematology Tags: Current Hematologic Malignancy Reports Source Type: journals
No advantage for chlorambucil maintenance therapy in gastric MALT lymphomaEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Content Type Journal ArticleCategory Clinical Trials ReportDOI 10.1007/s11899-009-0016-3Authors
James O. Armitage, University of Nebraska Medical Center Section of Oncology and Hematology Omaha USA
Journal Current Hematologic Malignancy ReportsOnline ISSN 1558-822XPrint ISSN 1558-8211
Journal Volume Volume 4
Journal Issue Volume 4, Number 3 / July, 2009 (Source: Current Hematologic Malignancy Reports)
Source: Current Hematologic Malignancy Reports - June 30, 2009 Category: Hematology Tags: Current Hematologic Malignancy Reports Source Type: journals
The role of bisphosphonates in multiple myelomaEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Abstract Multiple myeloma (MM) is the second most common hematologic malignancy and the most common malignancy to involve bone. More
than 85% of patients with MM have bone involvement, which can be devastating. Bisphosphonate therapy is the mainstay of treatment
for MM bone disease; it has decreased the frequency of skeletal events in MM and delayed their development. Further, the toxicity
of these drugs is low and generally manageable. Whether bisphosphonates have any antitumor effects in MM patients (in contrast
to what has been reported in preclinical models) is unclear and requires further study. Althoug...
Source: Current Hematologic Malignancy Reports - March 22, 2009 Category: Hematology Tags: Current Hematologic Malignancy Reports Source Type: journals
Treatment of relapsed and refractory myelomaEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
This article outlines some of the data underpinning the use of bortezomib, thalidomide, lenalidomide,
or combinations of these agents in the setting of relapsed myeloma, as well as a number of potential future agents or combinations
that may improve outcomes for patients with relapsed and refractory disease.
Content Type Journal ArticleDOI 10.1007/s11899-009-0014-5Authors
Jonathan KaufmanCharise GleasonSagar Lonial, Emory University Winship Cancer Institute 1365 Clifton Road, Building C, Room 4004 Atlanta GA 30322 USA
Journal Current Hematologic Malignancy ReportsOnline ISSN 1558-822XPrint ISSN 1558-8211
...
Source: Current Hematologic Malignancy Reports - March 22, 2009 Category: Hematology Tags: Current Hematologic Malignancy Reports Source Type: journals
The role of gemtuzumab ozogamicin in combination chemotherapy regimens for primary resistant or relapsed acute myeloid leukemiaEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Content Type Journal ArticleCategory Clinical Trials ReportDOI 10.1007/s11899-009-0008-3Authors
Hien K. DuongMatt Kalaycio
Journal Current Hematologic Malignancy ReportsOnline ISSN 1558-822XPrint ISSN 1558-8211
Journal Volume Volume 4
Journal Issue Volume 4, Number 2 / April, 2009 (Source: Current Hematologic Malignancy Reports)
Source: Current Hematologic Malignancy Reports - March 22, 2009 Category: Hematology Tags: Current Hematologic Malignancy Reports Source Type: journals
Clinical implications of
c-Kit
mutations in acute myelogenous leukemiaEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Abstract c-Kit is a receptor tyrosine kinase (RTK) with a pivotal role in melanogenesis, gametogenesis, and hematopoiesis. Aberrantly
activated RTK and related downstream signaling partners were identified as key elements in the molecular pathogenesis of several
malignancies. This finding culminated in a two-class model integrating constitutive activating and maturation arrest-inducing
mutations as key elements for the pathogenesis of acute myelogenous leukemia (AML). c-Kit is expressed by myeloblasts in about
60% to 80% of patients, and the most frequently observed activating RTK mutations in AML (next to F...
Source: Current Hematologic Malignancy Reports - March 22, 2009 Category: Hematology Tags: Current Hematologic Malignancy Reports Source Type: journals
Predicting the response of CML patients to tyrosine kinase inhibitor therapyEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Abstract Tyrosine kinase inhibitor (TKI) therapy has significantly changed the treatment paradigm for patients with chronic myeloid
leukemia (CML). The firs-tgeneration inhibitor, imatinib, has demonstrated remarkable efficacy in most chronic-phase patients.
Disease progression remains a significant risk for the first 2 to 3 years of TKI therapy, but the risk falls significantly
thereafter. Early recognition of each individual’s risk of progression may facilitate a customized approach to TKI therapy.
Using such an approach, drug selection and treatment intensity would be adjusted on the basis of each patie...
Source: Current Hematologic Malignancy Reports - March 22, 2009 Category: Hematology Tags: Current Hematologic Malignancy Reports Source Type: journals
Treatment of immunoglobulin light chain amyloidosisEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Abstract No therapy is uniformly effective in the management of immunoglobulin light chain amyloidosis (AL amyloidosis). Despite the
common generalization, therapy is highly effective. Options available to patients with AL amyloidosis include high-dose therapy,
but this is applicable to only about one fourth of patients. Therapies shown to be effective are based on alkylators, dexamethasone,
or combinations of an alkylator and steroids. In the past 5 years, novel agents previously shown to be effective in multiple
myeloma (eg, thalidomide, lenalidomide, and bortezomib) have been shown to have efficacy in the...
Source: Current Hematologic Malignancy Reports - March 22, 2009 Category: Hematology Tags: Current Hematologic Malignancy Reports Source Type: journals
Chronic myelogenous leukemia stem cells: What’s new?Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
This article reviews recent developments
in the biology and treatment of CML, specifically focusing on CML stem cells. Significant progress continues to be made in
our understanding of CML stem cell biology, which has wider implications within the cancer stem cell field. We are also beginning
to see the identification of novel therapies that specifically target the CML stem cell. These are exciting times in the quest
to cure CML.
Content Type Journal ArticleDOI 10.1007/s11899-009-0010-9Authors
Mhairi Copland, Gartnavel General Hospital Leukaemia Research Centre 1053 Great Western Road Glasgow G12 0YN UK
Jou...
Source: Current Hematologic Malignancy Reports - March 22, 2009 Category: Hematology Tags: Current Hematologic Malignancy Reports Source Type: journals
MicroRNA expression in acute myeloid leukemiaEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
This article reviews recent
studies that were focused on the alterations of microRNA expression in AML and their diagnostic and prognostic significance.
Content Type Journal ArticleDOI 10.1007/s11899-009-0012-7Authors
Guido Marcucci, The Ohio State University The Comprehensive Cancer Center A433B Starling-Loving Hall, 320 West 10th Avenue Columbus OH 43210 USAMichael D. RadmacherKrzysztof MrózekClara D. Bloomfield
Journal Current Hematologic Malignancy ReportsOnline ISSN 1558-822XPrint ISSN 1558-8211
Journal Volume Volume 4
Journal Issue Volume 4, Number 2 / April, 2009 (Source: Current Hematologic Malignancy Reports)
Source: Current Hematologic Malignancy Reports - March 22, 2009 Category: Hematology Tags: Current Hematologic Malignancy Reports Source Type: journals
Myelodysplastic syndrome: An update on diagnosis and therapyEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Abstract Myelodysplastic syndromes (MDS) are a diverse group of disorders characterized by disorderly and ineffective hematopoiesis.
Patients suffer morbidity from associated cytopenias that result in an increased risk of infection, transfusion-dependent
anemia, and bleeding. Despite the variable risk of transformation to acute leukemia, the majority of deaths are due to bone
marrow failure. No truly effective treatment exists for MDS, and therapy usually focuses on reducing or preventing complications
of the disease. Identification of potential cellular and molecular targets, such as epigenetic modification...
Source: Current Hematologic Malignancy Reports - December 24, 2008 Category: Hematology Tags: Current Hematologic Malignancy Reports Source Type: journals
Use of alemtuzumab and rituximab consolidation in CLL: Pros and consEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
This article describes various methods of assessing minimal
residual disease and presents data demonstrating that new therapeutic approaches can eliminate residual malignant cells at
the highest levels of sensitivity currently available. Although initial evidence suggests that the use of alemtuzumab induces
a survival benefit when used in the consolidation setting, important safety issues remain to be resolved before this approach
can be introduced in routine practice.
Content Type Journal ArticleDOI 10.1007/s11899-009-0006-5Authors
Thomas Elter, University of Cologne Department I of Internal Medicine Kerpener Str...
Source: Current Hematologic Malignancy Reports - December 24, 2008 Category: Hematology Tags: Current Hematologic Malignancy Reports Source Type: journals
New and old prognostic factors in polycythemia veraEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Abstract Polycythemia vera is a chronic myeloproliferative disorder affecting people in the sixth decade of life. The disease is considered
long-lasting; median survival exceeds 18 years. As thrombosis is the main complication during follow-up, scoring systems have
focused on the risk of thrombosis. Age over 60 years and prior thrombosis are considered the standard risk factors for thrombosis
and represent the state of the art for risk stratification in decision making regarding treatment. However, new disease-based
risk factors—leukocytosis and the JAK2V617F mutation burden—seem to be emerging as indica...
Source: Current Hematologic Malignancy Reports - December 24, 2008 Category: Hematology Tags: Current Hematologic Malignancy Reports Source Type: journals
The 2008 WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosisEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Abstract Several international working groups cooperated to propose new diagnostic guidelines for polycythemia vera (PV), essential
thrombocythemia (ET), and primary myelofibrosis (PMF) to the steering committee of the World Health Organization. Because
JAK2 mutation status presents a decisive diagnostic test in PV, this feature was introduced as a major criterion. Minor criteria,
such as characteristic bone marrow morphology, low erythropoietin level, and erythroid colony formation, were kept as supporting
parameters. In PMF, major diagnostic criteria were established by histologic features independent of t...
Source: Current Hematologic Malignancy Reports - December 24, 2008 Category: Hematology Tags: Current Hematologic Malignancy Reports Source Type: journals
Management of myelodysplastic syndromes in the geriatric patientEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Abstract The majority of patients with myelodysplastic syndromes (MDS) are older, and the incidence of these diseases is rising as
the population ages. Clinicians are often uncertain about how to identify patients who may benefit from specific treatment
strategies. The International Prognostic Scoring System is a widely used tool to assess risk of transformation to leukemia
and guide treatment decisions, but it fails to take into account many aspects of treating elderly patients, including comorbid
illness, secondary causes of MDS, prior therapy for MDS, and other age-related health, functional, cognitive, a...
Source: Current Hematologic Malignancy Reports - December 24, 2008 Category: Hematology Tags: Current Hematologic Malignancy Reports Source Type: journals
Alemtuzumab to treat refractory autoimmune hemolytic anemia or thrombocytopenia in chronic lymphocytic leukemiaEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Abstract Autoimmune hemolytic anemia (AIHA) and immune thrombocytopenic purpura (ITP) are recognized complications of chronic lymphocytic
leukemia (CLL) that can be life-threatening if not managed appropriately. Conventional therapies for these autoimmune disorders,
such as corticosteroids, splenectomy, and immunosuppressive agents, may not induce complete resolution in all patients, and
relapses are common. In recent years, monoclonal antibodies such as alemtuzumab and rituximab, already used successfully for
the management of lymphoproliferative disorders, have been shown to be effective in the treatment o...
Source: Current Hematologic Malignancy Reports - December 24, 2008 Category: Hematology Tags: Current Hematologic Malignancy Reports Source Type: journals
Do we know more about essential thrombocythemia because of
JAK2
V617F?Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
This article reviews its impact upon our knowledge regarding essential thrombocythemia. The discovery of JAK2V617F has led to the proposal that essential thrombocythemia, polycythemia vera, and primary myelofibrosis be discarded as
separate diagnoses, and the rationale for this change is discussed. Simplified diagnostic criteria based upon testing for
JAK2V617F are proposed. Interesting data are emerging regarding disease progression and risk of complications, specifically thrombosis,
pregnancy loss, and perhaps progression to myelofibrosis. The JAK2V617F allele burden is emerging as a potentially important risk factor,...
Source: Current Hematologic Malignancy Reports - December 24, 2008 Category: Hematology Tags: Current Hematologic Malignancy Reports Source Type: journals
The follicular lymphoma microenvironment: From tumor cell to host immunityEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Abstract Follicular lymphoma (FL) is a neoplasm derived from follicular germinal center cells. Like the normal components of this lymphoid
structure, FL cells interact with various immune cells, such as the follicular helper T cells, suppressor regulatory T cells,
dendritic cells, and histiocytes, that define the tumor microenvironment. Gene expression studies have shown that the nature
of the tumor microenvironment predicts survival in patients with FL and may influence the response to immunotherapy and risk
of transformation. The immune system may either promote or constrain tumor cell development, dependi...
Source: Current Hematologic Malignancy Reports - October 16, 2008 Category: Hematology Tags: Current Hematologic Malignancy Reports Source Type: journals
Beyond rituximab: The future of monoclonal antibodies in B-cell non-Hodgkin lymphomaEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Abstract The treatment of non-Hodgkin lymphoma (NHL) has changed dramatically since the introduction of rituximab, a monoclonal antibody
that binds to the B-cell transmembrane protein CD20 and causes lysis of the lymphoma cells. Since then, a number of additional
antibodies have been tested against other B-cell targets, resulting in variable efficacies. The goal of these newer agents
is to achieve similar or better response rates as seen with rituximab and perhaps demonstrate activity in rituximab-refractory
disease. Several of the antibodies have been investigated in combination with each other as well as w...
Source: Current Hematologic Malignancy Reports - October 16, 2008 Category: Hematology Tags: Current Hematologic Malignancy Reports Source Type: journals
Web alertEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Content Type Journal ArticleDOI 10.1007/s11899-008-0025-7
Journal Current Hematologic Malignancy ReportsOnline ISSN 1558-822XPrint ISSN 1558-8211
Journal Volume Volume 3
Journal Issue Volume 3, Number 4 / October, 2008 (Source: Current Hematologic Malignancy Reports)
Source: Current Hematologic Malignancy Reports - October 16, 2008 Category: Hematology Tags: Current Hematologic Malignancy Reports Source Type: journals
Familial chronic lymphocytic leukemiaEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
This article reviews current knowledge relating to inherited susceptibility to CLL and strategies that are being
used to identify disease-causing mutations.
Content Type Journal ArticleDOI 10.1007/s11899-008-0031-9Authors
Richard S. Houlston, Institute of Cancer Research Section of Cancer Genetics 15 Cotswold Road Sutton Surrey SM2 5NG UKDaniel Catovsky
Journal Current Hematologic Malignancy ReportsOnline ISSN 1558-822XPrint ISSN 1558-8211
Journal Volume Volume 3
Journal Issue Volume 3, Number 4 / October, 2008 (Source: Current Hematologic Malignancy Reports)
Source: Current Hematologic Malignancy Reports - October 16, 2008 Category: Hematology Tags: Current Hematologic Malignancy Reports Source Type: journals
Novel therapies in peripheral T-cell lymphomasEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Abstract Peripheral T-cell lymphomas (PTCLs) are a rare and heterogeneous group of disorders associated with a very poor prognosis.
Historically, treatment protocols have been largely based on regimens used to treat aggressive B-cell lymphomas; unfortunately,
the efficacy of these regimens has been suboptimal, with most patients experiencing relapse after initial therapy. An improved
understanding of the molecular biology, pathogenesis, and progression of these disorders has led to the development of a variety
of novel targeted agents that may improve outcomes in patients with PTCLs. The purpose of this revi...
Source: Current Hematologic Malignancy Reports - October 16, 2008 Category: Hematology Tags: Current Hematologic Malignancy Reports Source Type: journals
Mantle cell lymphoma: Frontline and salvage therapyEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Abstract Mantle cell lymphoma (MCL) is a therapeutic challenge because of its lower cure rate when compared with other lymphomas such
as diffuse large cell lymphoma. The current emphasis in the treatment of newly diagnosed MCL has been on intensifying chemotherapy,
but there is no consensus on the need to consolidate with autologous stem cell transplantation. These approaches, however,
have not resulted in a cure. Newer strategies include the use of models to aid in tailoring therapy. Likewise, autologous
stem cell consolidation does not cure relapsed disease. Because of its known graft-versus-lymphoma effec...
Source: Current Hematologic Malignancy Reports - October 16, 2008 Category: Hematology Tags: Current Hematologic Malignancy Reports Source Type: journals
FDG-PET scans in patients with lymphomaEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Abstract Lymphoma comprises a complex set of diseases, including Hodgkin and non-Hodgkin subtypes. An expected goal of management is
chronic disease control over decades in most patients with indolent subtypes, and cure is a realistic target for aggressive
histologies, including Hodgkin lymphoma. Making methods available to better assess prognosis and to more specifically tailor
therapy toward individual subtypes is a priority. Positron emission tomography using the tracer 18fluoro-2-deoxyglucose (FDG-PET) has become a valuable tool in the care of patients with lymphoma; it contributes information
on staging...
Source: Current Hematologic Malignancy Reports - October 16, 2008 Category: Hematology Tags: Current Hematologic Malignancy Reports Source Type: journals
New agents for the treatment of patients with acute lymphoblastic leukemiaEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Abstract Acute lymphoblastic leukemia (ALL) has a bimodal age distribution with a peak occurring during early childhood and a second
peak after age 45. Although all patients are treated with similar intensive chemotherapy regimens, good outcomes have occurred
more frequently in children than adults. Most children with ALL have been able to achieve a complete remission (CR) with an
induction rate of about 98% and a 5-year estimated event-free survival rate (EFS) rate of about 80%. Unfortunately, the results
for adults are less encouraging. Current adult treatment regimens result in CR rates approaching 80%, w...
Source: Current Hematologic Malignancy Reports - October 10, 2008 Category: Hematology Tags: Current Hematologic Malignancy Reports Source Type: journals
Role of minimal residual disease evaluation in leukemia therapyEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
This article discusses the methodologies available for productive MRD
testing and the clinical significance of the results.
Content Type Journal ArticleDOI 10.1007/s11899-008-0022-xAuthors
Dario Campana, St. Jude Children’s Research Hospital Department of Oncology 332 North Lauderdale Memphis TN 38105 USA
Journal Current Hematologic Malignancy ReportsOnline ISSN 1558-822XPrint ISSN 1558-8211
Journal Volume Volume 3
Journal Issue Volume 3, Number 3 / July, 2008 (Source: Current Hematologic Malignancy Reports)
Source: Current Hematologic Malignancy Reports - October 10, 2008 Category: Hematology Tags: Current Hematologic Malignancy Reports Source Type: journals
Acute lymphoblastic leukemia in adolescents and young adultsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Abstract Age at diagnosis remains one of the strongest prognostic factors in acute lymphoblastic leukemia (ALL), with older patients
having inferior outcomes compared with younger patients. Adolescents and young adults (AYAs) with ALL (age 15–30 years) represent
a patient subgroup with distinctive biology whose optimal therapy has yet to be determined. Compared with younger children
with ALL, AYAs are more likely to present with unfavorable presenting characteristics (such as high presenting leukocyte counts,
T-cell phenotype, and the Philadelphia chromosome). Additionally, AYAs with ALL experience more re...
Source: Current Hematologic Malignancy Reports - October 10, 2008 Category: Hematology Tags: Current Hematologic Malignancy Reports Source Type: journals
Late complications after treatment for Hodgkin lymphomaEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Abstract Long-term survivors of Hodgkin lymphoma face a number of late effects that can significantly affect the length and quality
of their life. These include increased risk of second malignancy, cardiovascular disease, pulmonary dysfunction, infections,
and endocrinopathy. Of these late effects, second malignancies and cardiac disease are the two leading contributors to the
excess mortality seen in long-term Hodgkin lymphoma survivors. An improved understanding of the range of late complications
after Hodgkin lymphoma therapy and the identification of treatment-related and patient-related risk factors can...
Source: Current Hematologic Malignancy Reports - October 10, 2008 Category: Hematology Tags: Current Hematologic Malignancy Reports Source Type: journals
Nodular lymphocyte-predominant Hodgkin lymphomaEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Abstract Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare subtype of Hodgkin lymphoma that differs from classic Hodgkin
lymphoma (cHL) with respect to histologic and clinical presentation. Because the prognosis of NLPHL in early unfavorable and
advanced stages is similar to that of cHL, treatment is similar. In contrast, early favorable-stage NLPHL has a better prognosis
than cHL. Thus, NLPHL in early favorable stages might be treated with reduced-intensity programs without compromising cure
rates. Because involved-field radiotherapy alone seems to be as effective as extended-field radiother...
Source: Current Hematologic Malignancy Reports - October 10, 2008 Category: Hematology Tags: Current Hematologic Malignancy Reports Source Type: journals
Pediatric non-Hodgkin lymphomaEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Abstract Non-Hodgkin lymphoma (NHL) accounts for 7% of cancer in children and adolescents in the United States, or approximately 1000
cases annually. NHL in the pediatric population differs from that observed in adult patients with respect to staging systems,
histologic subtypes of disease, treatment, and outcomes. Although more than 90% of pediatric NHL is of high-grade histology,
more than 80% of patients achieve long-term event-free survival with modern therapy. This review focuses on current treatments
for pediatric NHL and some of the differences between NHL observed in pediatric and adult patients.
...
Source: Current Hematologic Malignancy Reports - October 10, 2008 Category: Hematology Tags: Current Hematologic Malignancy Reports Source Type: journals
Web AlertEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Content Type Journal ArticleDOI 10.1007/s11899-008-0017-7
Journal Current Hematologic Malignancy ReportsOnline ISSN 1558-822XPrint ISSN 1558-8211
Journal Volume Volume 3
Journal Issue Volume 3, Number 3 / July, 2008 (Source: Current Hematologic Malignancy Reports)
Source: Current Hematologic Malignancy Reports - October 10, 2008 Category: Hematology Tags: Current Hematologic Malignancy Reports Source Type: journals
Approaches to treatment for acute lymphoblastic leukemia in adolescents and young adultsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Abstract Acute lymphoblastic leukemia affects infants, children, adolescents, and adults. Although most children have a high likelihood
of cure, outcomes in adults have much room for improvement. In between lies the adolescent and young adult population, not
only in terms of age but also in clinical success rates. This review describes biology, prognostic factors, and treatment
approaches in adolescents and young adults with acute lymphoblastic leukemia. Assessing the outcomes in adult and pediatric
clinical trials that enroll adolescents and young adults can be especially useful in determining how best to t...
Source: Current Hematologic Malignancy Reports - October 10, 2008 Category: Hematology Tags: Current Hematologic Malignancy Reports Source Type: journals
Web alertEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Content Type Journal ArticleDOI 10.1007/s11899-008-0010-1
Journal Current Hematologic Malignancy ReportsOnline ISSN 1558-822XPrint ISSN 1558-8211
Journal Volume Volume 3
Journal Issue Volume 3, Number 2 / April, 2008 (Source: Current Hematologic Malignancy Reports)
Source: Current Hematologic Malignancy Reports - April 29, 2008 Category: Hematology Tags: Current Hematologic Malignancy Reports Source Type: journals
